Investigation of HER-2 expression and its Correlation with clinicopathological parameters and overall survival of esophageal squamous cell carcinoma patients
| Autor: | Mehran Taheri, Mitra Heidarpour, Ali Akhavan, Parvin Goli, Amirhosein Kefayat |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
squamous cell carcinoma Human epidermal growth factor receptor 2 medicine.medical_specialty Lymphovascular invasion her-2 receptor Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Pathology Medicine RB1-214 esophageal cancer medicine.diagnostic_test business.industry Esophageal cancer medicine.disease Staining Exact test 030104 developmental biology 030220 oncology & carcinogenesis Cancer cell Immunohistochemistry Original Article business Infiltration (medical) Fluorescence in situ hybridization |
| Zdroj: | Iranian Journal of Pathology, Vol 15, Iss 4, Pp 274-281 (2020) Iranian Journal of Pathology |
| ISSN: | 2345-3656 1735-5303 |
| Popis: | Background & objective Human epidermal growth factor receptor 2 (HER-2) exhibits a vast range of expression in esophageal squamous cell carcinoma (ESCC) patients as a biomarker. This paper aimed to investigate HER-2 expression and clinicopathological parameters of esophageal SCC. Methods HER-2 expression was assessed in 102 ESCC patients by immunohistochemistry. The HER-2 staining intensity , according to the Gastric HER2 Biomarker1.0.0.1 version of the college of American pathologists (CAP) protocol for gastric and gastroesophageal junction cancers, was graded as 0 (no reactivity in any of the cancer cells' membranes); 1+ (pale or hardly noticeable reactivity in the membrane of cancer cells' cluster [≥ 5 neoplastic cells] regardless of the positive cancer cells' percentage); 2+ (weak-to-moderate complete, basolateral, or lateral membranous reactivity regardless of the positive cancer cells' percentage); and 3+ ( strong complete, basolateral, or lateral reactivity in the membrane of the cancer cell cluster regardless of the positive cancer cells' percentage).In this regard, 3+ scored samples were considered as positive. If HER-2 expression was scored 2+, an additional fluorescence in situ hybridization (FISH) was performed. Fisher's exact test was employed for investigating the correlation of HER-2 expression status with patients' clinicopathological characteristics (including age, gender, tumor location, stage, grade, infiltration level, venous invasion, lymphatic invasion, and tumor recurrence). Kaplan-Meier analysis was done for the patients' survival assessments. Results Five patients (~5%) were HER-2 positive and no significant association was observed between HER-2 expression and clinicopathological properties. In addition, HER-2 expression status exhibited no significant association with the patients' overall survival (P=0.9299). Conclusion HER-2 is not a suitable prognostic biomarker for Iranian ESCC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|